



Betamethasone Injection Formulation

Version 4.5	Revision Date: 09.04.2021		DS Number: 274110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017		
SECTION 1: Identification of the substance/mixture and of the company/undertaking						
1.1 Produc	t identifier					
Trade name			Betamethasone In	njection Formulation		
1.2 Relevant identified uses of tl Use of the Sub- stance/Mixture			substance or mixto Pharmaceutical	ure and uses advised against		
1.3 Details	of the supplier of the	saf	ety data sheet			
Compa	any	:	Shotton Lane	ington NU - Great Britain		
Teleph	one	:	44 1 670 59 30 00)		

E-mail address of person : EHSSTEWARD@organon.com responsible for the SDS

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

	:	
	:	Danger
Hazard statements	:	 H360D May damage the unborn child. H372 Causes damage to organs through prolonged or repeated exposure. H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements	:	Prevention:

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 1274110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017
		P264 Wash skin P273 Avoid relea	ecial instructions before use. thoroughly after handling. ase to the environment. ective gloves/ protective clothing/ eye protec- n.
		Response: P308 + P313 IF attention. P391 Collect spi	exposed or concerned: Get medical advice/

Hazardous components which must be listed on the label:

betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No.	Classification	Concentration (% w/w)
betamethasone	Registration number 378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Im- mune system, mus- cle, thymus gland, Blood, Adrenal gland) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 1,000	>= 0.3 - < 1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice

- : In the case of accident or if you feel unwell, seek medical advice immediately.
 - When symptoms persist or in all cases of doubt seek medical advice.

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

Version 4.5	Revision Date: 09.04.2021	-	9S Number: 74110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017			
Protection of first-aiders		:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).				
If inhaled		:	If inhaled, remove to fresh air. Get medical attention.				
In case of skin contact		:	In case of contact, immediately flush skin with soap and plent of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.				
In cas	se of eye contact	:		water as a precaution. Intion if irritation develops and persists.			
lf swa	allowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.				
I.2 Most i	mportant symptoms a	nd e	ffects, both acu	te and delayed			
Risks	Risks		: May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.				
1.3 Indica	tion of any immediate	meo	lical attention ar	nd special treatment needed			
Treat	ment	:	Treat symptoma	tically and supportively.			
SECTION	1 5: Firefighting meas	sur	es				
5.1 Exting	uishing media						
_	Juishing media ble extinguishing media	:	Water spray Alcohol-resistan Carbon dioxide Dry chemical				
Suita	ble extinguishing media	:	Alcohol-resistan Carbon dioxide Dry chemical				
Suita Unsu media	ble extinguishing media itable extinguishing	:	Alcohol-resistan Carbon dioxide Dry chemical None known.	(CO2)			
Suita Unsu media 5.2 Specia	ble extinguishing media itable extinguishing a al hazards arising from ific hazards during fire-	: the	Alcohol-resistan Carbon dioxide Dry chemical None known.	(CO2)			
Suita Unsu media 5.2 Specia Spec fightir	ble extinguishing media itable extinguishing a al hazards arising from ific hazards during fire-	: the	Alcohol-resistan Carbon dioxide Dry chemical None known.	(CO2) sixture			
Suita Unsu media 5.2 Specia Spec fightir Haza ucts	ble extinguishing media itable extinguishing a al hazards arising from ific hazards during fire- ng	: the	Alcohol-resistan Carbon dioxide Dry chemical None known.	(CO2) sixture			

Special protective equipment : In the event of fire, wear self-contained breathing apparatus.

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 1274110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017	
for firefighters		Use personal protective equipment.		
Specif ods	ic extinguishing meth-	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. aged containers from fire area if it is safe to do	

SECTION 6: Accidental release measures

6.1 Personal precautions, protec	tive	e equipment and emergency procedures
Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
6.3 Methods and material for cor	ntai	nment and cleaning up
Methods for cleaning up	:	Soak up with inert absorbent material. For large spills, provide dyking or other appropriate contain- ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	: Do not get on skin or clothing.

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

Version 4.5	Revision Date: 09.04.2021	SDS Number: 1274110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017		
Hygiene measures		 Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 			
7.2 Condi	tions for safe storage,		-		
	irements for storage and containers		erly labelled containers. Store locked up. Keep . Store in accordance with the particular national		
Advid	ce on common storage	: Do not store Strong oxidiz Organic pero Explosives Gases			
7.3 Speci	fic end use(s)				
-	ific use(s)	: No data avail	able		

SECTION 8: Exposure controls/personal protection

8.1 Control parameters


Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
betamethasone	378-44-9	TWA	1 µg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 μg/100 cm²	Internal

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.





Betamethasone Injection Formulation

Version 4.5	Revision Date: 09.04.2021	-	OS Number: 74110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017		
Use If ha tain	Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other con- tainment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.					
Per	sonal protective equipm	nent				
mists or aerosols, wear the appropr Wear a faceshield or other full face		nment or activity involves dusty conditions,				
Har	nd protection					
l	Material	:	Chemical-resistar	t gloves		
	Remarks n and body protection	:	task being perform posable suits) to a	aboratory coat. arments should be used based upon the ned (e.g., sleevelets, apron, gauntlets, dis- avoid exposed skin surfaces. legowning techniques to remove potentially		
	spiratory protection	:	If adequate local e sure assessment ommended guide Equipment should	exhaust ventilation is not available or expo- demonstrates exposures outside the rec- lines, use respiratory protection. I conform to BS EN 143		
Filte	er type	:	Particulates type	(P)		

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

· · · · · · · · · · · · · · · · · · ·		
Appearance	:	liquid
Colour	•	No data available
Odour	÷	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available
range		
Flash point	:	No data available
Evaporation rate		No data available
Evaporation rate	•	
Flammability (solid, gas)	:	Not applicable
, , , , , , , , , , , , , , , , , , ,		
Flammability (liquids)	:	No data available
Upper explosion limit / Upper	:	No data available
flammability limit		

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

Vers 4.5	sion Revision Date: 09.04.2021	SDS Number:Date of last issue: 05.10.20201274110-00011Date of first issue: 12.02.2017	
Lower explosion limit / Lower flammability limit		: No data available	
	Vapour pressure	: No data available	
	Relative vapour density	: No data available	
	Relative density	: No data available	
	Density	: No data available	
	Solubility(ies) Water solubility Partition coefficient: n- octanol/water Auto-ignition temperature	No data availableNot applicableNo data available	
	Decomposition temperature	: No data available	
	Viscosity Viscosity, kinematic	: No data available	
	Explosive properties	: Not explosive	
	Oxidizing properties	: The substance or mixture is not classified as oxidizing.	
9.2	Other information Particle size	: Not applicable	

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions Hazardous reactions

: Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid	: Oxidizing agents
--------------------	--------------------

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

Version 4.5	Revision Date: 09.04.2021		DS Number: 74110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017
SECTION	N 11: Toxicological ir	nfor	mation	
11.1 Infor	mation on toxicologica	al ef	fects	
	nation on likely routes of			
	e toxicity lassified based on availa	able	information.	
Prod Acute	uct: inhalation toxicity	:	Acute toxicity esti Exposure time: 4 Test atmosphere: Method: Calculati	h dust/mist
<u>Com</u>	ponents:			
	nethasone:	:	LD50 (Rat): > 5,0	00 ma/ka
	, e.e., terneny		LD50 (Mouse): >	
Acute	e inhalation toxicity	:	LC50 (Rat): 0.4 m Exposure time: 4	
	corrosion/irritation lassified based on availa	able	information.	
<u>Com</u>	ponents:			
betar Spec Resu		:	Rabbit Mild skin irritation	
	ous eye damage/eye irr lassified based on availa			
<u>Com</u>	ponents:			
betar Spec Resu		:	Rabbit No eye irritation	

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

ersion 5	Revision Date: 09.04.2021	SDS Number: 1274110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017
<u>Comp</u>	oonents:		
		: Dermal : Guinea pig : Weak sensitiz	er
	cell mutagenicity assified based on ava	ilable information.	
Comp	oonents:		
	nethasone: coxicity in vitro	: Test Type: Ba Result: negati	acterial reverse mutation assay (AMES)
		Test Type: In Result: negati	vitro mammalian cell gene mutation test ve
		Test Type: Ch Result: positiv	rromosome aberration test in vitro /e
Genot	oxicity in vivo	: Test Type: Ma cytogenetic as Species: Mou Application Ro Result: equivo	se pute: Oral
Germ sessm	cell mutagenicity- As- nent	: Weight of evic cell mutagen.	dence does not support classification as a gern
	nogenicity assified based on ava	ilable information.	
-	oductive toxicity lamage the unborn ch	ild.	
Comp	oonents:		
	nethasone: s on foetal develop-	Developmenta	bit oute: Intramuscular al Toxicity: LOAEL: 0.05 mg/kg body weight oxicity, Malformations were observed.
		Developmenta	oute: Subcutaneous al Toxicity: LOAEL: 0.42 mg/kg body weight mations were observed.
		Developmenta	se oute: Intramuscular al Toxicity: LOAEL: 1 mg/kg body weight mations were observed.

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

5	Revision Date: 09.04.2021	SDS Number: 1274110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017			
Reproductive toxicity - As- sessment		: Clear evidence animal experin	e of adverse effects on development, based on nents.			
	- single exposure assified based on avai	lable information.				
sтот	- repeated exposure					
	es damage to organs th		repeated exposure.			
	onents:					
betam	ethasone:					
Target	t Organs	: Pituitary gland	, Immune system, muscle, thymus gland, Blood			
Assessment		Adrenal gland : Causes damag exposure.	Adrenal gland : Causes damage to organs through prolonged or repeated			
Repea	ated dose toxicity					
<u>Comp</u>	onents:					
betam	ethasone:					
Specie	es	: Rabbit				
LOAE		: 0.05 %				
	ation Route	: Skin contact				
	ure time t Organs	: 10 - 30 d : Pituitary gland	, Immune system, muscle			
Targer	Organs	. Fitultary giariu	, minune system, muscle			
Specie		: Rat				
LOAE		: 0.05 %				
	ation Route	: Skin contact				
	ure time t Organs	: 8 Weeks : thymus gland				
rarger	organs	. trymus giana				
Specie		: Mouse				
LOAE		: 0.1 %				
	ation Route	: Skin contact				
	ure time t Organs	: 8 Weeks : thymus gland				
U	0					
Specie		: Dog				
LOAE		: 0.05 mg/kg : Oral				
	ation Route	: 28 d				
	ure time	. 780				

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

Vers 4.5	ion	Revision Date: 09.04.2021		0S Number: 74110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017			
	Experience with human exposure							
	Components:							
	betame Inhalati Skin co	-	:	Target Organs: A Symptoms: Redn	drenal gland ess, pruritis, Irritation			
SEC	TION	12: Ecological infor	ma	tion				
12.1	Toxicit	ty						
	Compo	onents:						
	Toxicity	ethasone: / to daphnia and other : invertebrates	:	EC50 (Americam) Exposure time: 96				
	Toxicity plants	/ to algae/aquatic	:	mg/l Exposure time: 72 Method: OECD T				
				mg/l Exposure time: 72 Method: OECD To				
	Toxicity icity)	/ to fish (Chronic tox-	:	NOEC: 0.052 mg/ Exposure time: 32 Species: Pimepha Method: OECD T	2 d ales promelas (fathead minnow)			
				NOEC: 0.07 µg/l Exposure time: 2' Species: Oryzias Method: OECD Te	latipes (Japanese medaka)			
		/ to daphnia and other invertebrates (Chron- ity)		NOEC: 8 mg/l Exposure time: 2 ⁴ Species: Daphnia Method: OECD Te	magna (Water flea)			
	M-Fact toxicity	or (Chronic aquatic)	:	1,000				
		tence and degradabil a available	ity					

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

Versi 4.5	on Revision Date: 09.04.2021		S Number: 74110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017
12.3	Bioaccumulative potential			
<u>(</u>	Components:			
I	betamethasone:			
	Partition coefficient: n- octanol/water	:	log Pow: 2.11	
12.4	Mobility in soil			
I	No data available			
12.5	Results of PBT and vPvB	asses	sment	
ļ	Product:			
,	Assessment	:	to be either persis	ixture contains no components considered stent, bioaccumulative and toxic (PBT), or ind very bioaccumulative (vPvB) at levels of
12.6	Other adverse effects			
1	Product:			
	Endocrine disrupting poten- ial	:	ered to have ender REACH Article 57	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.
SEC	TION 13: Disposal cons	idera	tions	

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in
	discussion with the waste disposal authorities.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN	:	UN 3082
ADR	:	UN 3082
RID	:	UN 3082
IMDG	:	UN 3082
ΙΑΤΑ	:	UN 3082

14.2 UN proper shipping name

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

Version 4.5	Revision Date: 09.04.2021		OS Number: 74110-00011	Date of last issue: 05.10.2020 Date of first issue: 12.02.2017
ADN		:	ENVIRONMENT N.O.S. (betamethasone)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
ADR		:	ENVIRONMENT N.O.S. (betamethasone)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
RID		:	ENVIRONMENT N.O.S. (betamethasone)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
IMDO	3	:	ENVIRONMENT N.O.S. (betamethasone)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
ΙΑΤΑ	۱.	:	Environmentally (betamethasone)	hazardous substance, liquid, n.o.s.
14.3 Tran	sport hazard class(es)			
ADN		:	9	
ADR		:	9	
RID		:	9	
IMDO	G	:	9	
ΙΑΤΑ	۱.	:	9	
14.4 Pacl	king group			
Class	ing group sification Code ard Identification Number	:	III M6 90 9	
ADR Pack Class Haza Labe	ing group sification Code ard Identification Number	:	9 III M6 90 9 (-)	
Class	ing group sification Code ard Identification Number Is	:	III M6 90 9	
Labe	ting group	:	III 9 F-A, S-F	
	A (Cargo) ing instruction (cargo	:	964	
	ing instruction (LQ)	:	Y964	

according to Regulation (EC) No. 1907/2006



Betamethasone Injection Formulation

Vers 4.5	sion	Revision Date: 09.04.2021	SDS Number: 1274110-00011		Date of last issue: 05.10.2020 Date of first issue: 12.02.2017
	Packin Labels	g group	:	III Miscellaneous	
	Packin ger aire Packin	g instruction (LQ) g group	:	964 Y964 III Miscellaneous	
14.5		onmental hazards	•	Miscellarieous	
	ADN Enviroi	nmentally hazardous	:	yes	
	ADR Enviro	nmentally hazardous	:	yes	
	RID Enviro	nmentally hazardous	:	yes	
	IMDG Marine	pollutant	:	yes	
		Passenger) nmentally hazardous	:	yes	
		Cargo) nmentally hazardous	:	yes	

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) REACH - Candidate List of Substances of Very High		Conditions of restriction for the fol- lowing entries should be considered: Number on list 3 Not applicable
Concern for Authorisation (Article 59).		
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (EC) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable



according to Regulation (EC) No. 1907/2006

Betamethasone Injection Formulation

Versio 4.5	on	Revision Date: 09.04.2021	-	0S Number: 74110-00011		ast issue: 05.10.2 irst issue: 12.02.2		
	Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.							
E	Ξ1			ENVIRONMENTA HAZARDS	AL.	Quantity 1 100 t	Quantity 2 200 t	
C	Other r	egulations:						
v T	Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable. Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.							
Г	The co	mponents of this pro	duc	t are reported in t	the follow	ing inventories:	1	
A	AICS		:	not determined				
٢	DSL		:	not determined				
I	ECSC		:	not determined				
	15.2 Chemical safety assessment A Chemical Safety Assessment has not been carried out.							
SEC	TION	16: Other information	on					
C	Other ir	nformation	:	Items where chan are highlighted in lines.			e previous version by two vertical	
F	Full tex	t of H-Statements						
F	H330		:	Fatal if inhaled.				
	H360D		:	May damage the				
F	-1372		:	Causes damage t exposure.	to organs t	hrough prolonge	d or repeated	
F	H410		:	Very toxic to aqua	atic life with	h long lasting effe	ects.	
F	Full tex	t of other abbreviation	ons					
-	Acute T		:	Acute toxicity				
		: Chronic	:	Long-term (chron		hazard		
	Repr.		:	Reproductive toxi				
5	STOT F		÷	Specific target or	yan toxicity	y - repeated expo	bsure	

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of



Betamethasone Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 05.10.2020
4.5	09.04.2021	1274110-00011	Date of first issue: 12.02.2017

Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

compile the Safety Data Sheet

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the m	Classification procedure:	
Repr. 1B	H360D	Calculation method
STOT RE 1	H372	Calculation method
Aquatic Chronic 1	H410	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN